Background
Incretin-based therapies yagara ichizivikanwa kuti inovandudza ese ari mavirikudzora glucose yeropauyekuderedza uremu hwemuviri. Traditional incretin mishonga inonyanya kunangaGLP-1 receptor, apoTirzepatideinomiririra chizvarwa chitsva che“twincretin” vamiririri — kuita basazvose GIP (glucose-inotsamira insulinotropic polypeptide)uyeGLP-1receptors.
Ichi chiito chehuviri chakaratidzwa kuwedzera mabhenefiti emetabolism uye kukurudzira kudzikira uremu uchienzaniswa neGLP-1 agonist chete.
Iyo SURMOUNT-1 Yekudzidza Dhizaini
SURMOUNT-1aiva arandomized, kaviri-mapofu, chikamu 3 kliniki yekuedzayakaitwa munzvimbo dze119 munyika pfumbamwe.
Vatori vechikamu vaisanganisira vakuru vaive:
- Obese(BMI ≥ 30), kana
- Overweight(BMI ≥ 27) ine kanenge kamwe-kamwe kunoenderana nehuremu comorbidity (semuenzaniso, hypertension, dyslipidemia, apnea yekurara, kana chirwere chemoyo).
Vanhu vane chirwere cheshuga, kushandiswa kwemishonga ichangoburwa-kuderedza uremu, kana kuvhiyiwa kwebariatric vasati vabatanidzwa.
Vatori vechikamu vakapihwa zvisina tsarukano kuti vagamuchire kamwe-vhiki majekiseni e:
- Tirzepatide 5 mg, 10 mg, 15 mg, kana
- Placebo
Vese vatori vechikamu vakagamuchirawo mararamiro ehupenyu:
- A caloric kushomeka kwe500 kcal / zuva
- Dai wangoMaminitsi 150 ekurovedza muviri pavhiki
Kurapwa kwacho kwakagaramavhiki makumi manomwe nemaviri, kusanganisira a20-vhiki dose-kuwedzera chikamuinoteverwa ne52-vhiki yekuchengetedza nguva.
Results Overview
Zvose zve2,359 vatori vechikamuvakanyoreswa.
Avhareji yezera yaive44.9 makore, 67.5% vaive vakadzi, nekurevesauremu hwemuviri we104.8 kguyeBMI ye38.0.
Kurevesa Uremu hweMuviri paVhiki 72
| Dose Group | % Kuchinja Kwehuremu | Kuchinja Kwehuremu (kg) | Kuwedzera Kurasikirwa vs Placebo |
|---|---|---|---|
| 5 mg | -15.0% | -16.1 kg | -13.5% |
| 10 mg | -19.5% | -22.2 kg | -18.9% |
| 15 mg | -20.9% | -23.6 kg | -20.1% |
| Placebo | -3.1% | -2.4 kg | - |
Tirzepatide yakawana 15-21% inoreva kuderedza uremu hwemuviri, kuratidzira zvakajeka zvinotarisana nedosi.
Chikamu cheVatori Vechikamu Vari Kuwana Chinangwa Kureruka
| Kuderedza uremu (%) | 5 mg | 10 mg | 15 mg | Placebo |
|---|---|---|---|---|
| ≥5% | 85.1% | 88.9% | 90.9% | 34.5% |
| ≥10% | 68.5% | 78.1% | 83.5% | 18.8% |
| ≥15% | 48.0% | 66.6% | 70.6% | 8.8% |
| ≥20% | 30.0% | 50.1% | 56.7% | 3.1% |
| ≥25% | 15.3% | 32.3% | 36.2% | 1.5% |
Kupfuura hafuyevatori vechikamu vachigamuchira≥10 mgTirzepatide yakawanikwa≥20% kuderedza uremu, kuswedera kune chiitiko chinoonekwa nekuvhiyiwa kwebariatric.
Metabolic uye Cardiovascular Benefits
Kuenzaniswa ne placebo, Tirzepatide yakagadziridzwa zvakanyanya:
- Kutenderera kwechiuno
- Systolic blood pressure
- Lipid profile
- Kutsanya insulin mazinga
Pakati pevatori vechikamu vaneprediabetes, 95.3% yakadzokera kune yakajairika mazinga eglucose, zvichienzaniswa ne61.9%muboka re placebo - kuratidza Tirzepatide kwete chete rubatsiro mukuderedza uremu asiwo inovandudza glucose metabolism.
Kuchengeteka uye Kushivirira
Migumisiro yainyanyozivikanwa yaivagastrointestinal, kusanganisirakuda kurutsa, manyoka, nekuzvimbirwa, kazhinji zvinyoro uye zvenguva pfupi.
The discontinuation rate nekuda kweakaipa zviitiko zvaive zvakaenzana4–7%.
Rufu rushoma rwakaitika panguva yekutongwa, kunyanya kwakabatanaCOVID 19, uye dzakanga dzisina hukama zvakananga nemushonga wekudzidza.
Hapana misiyano yakakosha yakaonekwa mumatambudziko ane chekuita nenduru.
Kukurukurirana
Mararamiro ekugadzirisa ega (kudya uye kurovedza muviri) anowanzo gadzira chete~ 3% yevhareji yekurasikirwa, sezvinoonekwa muboka re placebo.
Mukupesana, Tirzepatide yakagonesa15-21% kuderedzwa kwehuremu hwemuviri, anomiririra a5-7 nguva yakakura kuita.
Kuenzaniswa ne:
- Madrugs ekuderedza uremu:kazhinji kuwana 5-10% kurasikirwa
- Bariatric Surgery:inowana > 20% kurasikirwa
Tirzepatide inovhara mukaha pakati pe pharmacologic uye kupindira kwekuvhiya - kupasimba, kwete-invasive uremu kuderedza.
Zvakakosha, kunetseka pamusoro pekuwedzera kweglucose metabolism hakuna kuonekwa. Pane zvinopesana, Tirzepatide yakavandudza insulin senzwi uye yakadzoreredza prediabetes muvazhinji vatori vechikamu.
Nekudaro, muyedzo uyu wakafananidza Tirzepatide ne placebo - kwete zvakanangana nazvoSemaglutide.
Kuenzanisa kwemusoro-kune-musoro kunodiwa kuti uone kuti ndeupi mumiririri anogadzira kurasikirwa kukuru.
Mhedziso
Kune vanhu vakuru vane kufutisa kana kuwandisa uye zvine hukama necomorbidities, kuwedzerakamwe-vhiki nevhiki Tirzepatidekune yakarongeka mararamiro chirongwa (kudya + kurovedza muviri) kunogona kutungamira kune:
- 15-21% avhareji yekuderedza uremu hwemuviri
- Yakakosha metabolic kunatsiridza
- High tolerability uye kuchengeteka
Tirzepatide nokudaro inomiririra kurapa kunoshanda uye kwekiriniki kwakagadziriswa kwekugara, kutariswa nekurapa uremu manejimendi.
Nguva yekutumira: Oct-16-2025